JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

  NCT03605836

  Conditions:   Attention Deficit Disorder;   Attention Deficit Hyperactivity Disorder
  Interventions:   Drug: Centanafadine SR;   Other: Placebo
  Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
  Recruiting
• 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).

  NCT04154878

  Conditions:   Diastolic Heart Failure;   Left Ventricular Diastolic Dysfunction;   Left Ventricular Diastolic Collapse
  Intervention:  
  Sponsor:   Florida Hospital
  Recruiting
• A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function

  NCT04136444

  Conditions:   Healthy Study Participants;   Impaired Hepatic Function
  Intervention:   Drug: Padsevonil
  Sponsor:   UCB Biopharma S.P.R.L.
  Recruiting
• Fine Needle Biopsy of Solid Pancreatic Mass Lesions

  NCT04085055

  Condition:   Solid Tumor
  Intervention:   Diagnostic Test: Solid pancreatic mass lesion biopsy
  Sponsor:   Florida Hospital
  Recruiting
• Renal PK Study of LC350189

  NCT04066712

  Conditions:   Gout;   Hyperuricemia
  Intervention:   Drug: LC350189 200 mg
  Sponsor:   LG Chem
  Recruiting
• Duodenoscope Assessment Tool Development

  NCT04004533

  Condition:   Endoscopy
  Intervention:   Procedure: endoscopy
  Sponsor:   Florida Hospital
  Recruiting
• Endoscopic Ultrasound vs Percutaneous Route for Biopsy

  NCT04003766

  Condition:   Liver Biopsy
  Intervention:   Diagnostic Test: biopsy
  Sponsor:   Florida Hospital
  Recruiting
• Radiation Exposure Assessment in Fluoroscopy

  NCT03985488

  Conditions:   Fluoroscopy; Adverse Effect;   Radiation Exposure
  Intervention:   Radiation: Radiation exposure
  Sponsor:   Florida Hospital
  Recruiting
• CharacterIzation of Adult Onset Autoimmune Diabetes

  NCT03971955

  Condition:   Diabetes
  Interventions:   Other: Mixed Meal Test;   Other: Dual Energy X-Ray Absorptiometry (DEXA);   Procedure: Adipose Tissue Biopsy
  Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
  Recruiting
• Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

  NCT03963895

  Conditions:   End Stage Renal Disease;   Thrombosis
  Interventions:   Drug: AB002;   Drug: placebo
  Sponsors:   Aronora, Inc.;   Celerion
  Recruiting
• The Role of Microbiome Reprogramming on Liver Fat Accumulation

  NCT03914495

  Condition:   NAFLD
  Interventions:   Dietary Supplement: Inulin;   Dietary Supplement: Placebo
  Sponsor:   Translational Research Institute for Metabolism and Diabetes, Florida
  Recruiting
• Exploration of Patient Ethics and Communication Excellence (PEACE) Rounds

  NCT03874676

  Condition:   Resilience
  Intervention:   Other: PEACE Rounds
  Sponsor:   Florida Hospital
  Recruiting
• Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

  NCT03713684

  Condition:   Type 2 Diabetes Mellitus
  Interventions:   Drug: Efpeglenatide SAR439977;   Drug: Placebo;   Drug: Insulin glargine
  Sponsor:   Sanofi
  Recruiting
• Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

  NCT03589781

  Condition:   Prostate Cancer
  Interventions:   Dietary Supplement: Mikei Red Reishi Essence EX;   Dietary Supplement: Placebo
  Sponsor:   Nikkei (Canada) Marketing Limited
  Recruiting
• Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

  NCT04154670

  Conditions:   Healthy;   Renal Insufficiency
  Intervention:   Biological: MGTA-145
  Sponsor:   Magenta Therapeutics, Inc.
  Recruiting
• Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

  NCT03961932

  Conditions:   Renal Impairment;   Healthy Participants
  Intervention:   Drug: Linzagolix
  Sponsor:   ObsEva SA
  Recruiting
• Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

  NCT03873038

  Conditions:   Renal Dialysis;   Kidney Failure, Chronic
  Interventions:   Drug: MK-2060;   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03014648

  Condition:   Advanced Non-small Cell Lung Cancer
  Intervention:   Drug: Atezolizumab
  Sponsors:   Liza Villaruz, MD;   Genentech, Inc.
  Recruiting
• Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

  NCT03962049

  Conditions:   Hepatic Impairment;   Healthy Participants
  Intervention:   Drug: Linzagolix
  Sponsor:   ObsEva SA
  Recruiting
• Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

  NCT03757351

  Condition:   Amyotrophic Lateral Sclerosis
  Interventions:   Drug: DNL747;   Drug: Placebo
  Sponsor:   Denali Therapeutics Inc.
  Recruiting
• Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort

  NCT04097704

  Condition:   Hepatic Insufficiency
  Intervention:  
  Sponsor:   Celgene
  Recruiting
• A Study of Tirzepatide in Participants With Impaired Liver Function

  NCT03940742

  Condition:   Hepatic Insufficiency
  Intervention:   Drug: Tirzepatide
  Sponsor:   Eli Lilly and Company
  Recruiting
• A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

  NCT03920865

  Condition:   Muscular Atrophy, Spinal
  Intervention:   Drug: Risdiplam
  Sponsor:   Hoffmann-La Roche
  Recruiting
• TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

  NCT03856099

  Condition:   Recurrent Glioblastoma
  Intervention:   Drug: TTAC-0001
  Sponsor:   PharmAbcine
  Recruiting
• Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

  NCT03611569

  Conditions:   Healthy;   Parkinson Disease
  Interventions:   Drug: Lu AF82422;   Drug: Placebo
  Sponsor:   H. Lundbeck A/S
  Recruiting
• Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

  NCT02465268

  Conditions:   Glioblastoma Multiforme;   Glioblastoma;   Malignant Glioma;   Astrocytoma, Grade IV;   GBM
  Interventions:   Biological: pp65-shLAMP DC with GM-CSF;   Biological: unpulsed PBMC and saline;   Drug: Td;   Drug: Saline;   Biological: pp65-flLAMP DC with GM-CSF
  Sponsors:   University of Florida;   National Cancer Institute (NCI)
  Recruiting
• Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

  NCT04091061

  Conditions:   Hepatic Impairment;   Healthy Volunteers
  Intervention:   Drug: PF-06865571 100 mg
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

  NCT04016077

  Conditions:   Hepatic Impairment;   Healthy Participants
  Intervention:   Drug: PF-06651600 30 mg
  Sponsor:   Pfizer
  Recruiting
• A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

  NCT03902002

  Condition:   Hepatic Impairment
  Intervention:   Drug: Omaveloxolone 50 mg capsules
  Sponsor:   Reata Pharmaceuticals, Inc.
  Recruiting
• ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

  NCT03295734

  Conditions:   Hypertension;   Aging;   Sedentary Lifestyle
  Interventions:   Behavioral: Aerobic exercise;   Drug: Perindopril;   Drug: Losartan;   Drug: HCTZ
  Sponsors:   University of Alabama at Birmingham;   University of Colorado, Denver;   Translational Research Institute for Metabolism and Diabetes, Advent Health
  Recruiting
• Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types

  NCT02772276

  Condition:   Acute Kidney Injury
  Interventions:   Drug: MB-102;   Drug: Iohexol;   Device: QuantumLeap;   Device: Radiance;   Device: Brilliance
  Sponsor:   MediBeacon
  Recruiting
• To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.

  NCT04155645

  Conditions:   Dyslipidemia;   Type 2 Diabetes
  Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
  Sponsors:   AstraZeneca;   Parexel
  Recruiting
• A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

  NCT03986944

  Condition:   Endometriosis
  Interventions:   Drug: Placebo linzagolix tablets and Placebo Add-back capsule;   Drug: Placebo linzagolix and linzagolix tablets and Placebo Add-back capsule;   Drug: Placebo linzagolix and linzagolix tablets and Add-back capsule
  Sponsor:   ObsEva SA
  Recruiting
• Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors

  NCT03206450

  Conditions:   Cancer Survivor;   Osteosarcoma
  Interventions:   Procedure: Biospecimen Collection;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Spanish Intervention for Caregivers of Veterans With Stroke

  NCT03142841

  Condition:   Depression
  Intervention:   Other: RESCUE Problem Solving Intervention
  Sponsor:   VA Office of Research and Development
  Recruiting
• A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561

  Condition:   Ulcerative Colitis (UC)
  Intervention:  
  Sponsor:   AbbVie
  Recruiting
• Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

  NCT00632853

  Condition:   Lung Cancer
  Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause

  NCT04003389

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

  NCT04003155

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

  NCT03233711

  Conditions:   Anal Basaloid Carcinoma;   Anal Canal Cloacogenic Carcinoma;   Anal Margin Squamous Cell Carcinoma;   Stage IIB Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
  Interventions:   Biological: Nivolumab;   Other: Patient Observation
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH

  NCT03028740

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Cenicriviroc;   Drug: Placebo
  Sponsor:   Tobira Therapeutics, Inc.
  Recruiting
• Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

  NCT02958865

  Condition:   Ulcerative Colitis
  Interventions:   Drug: PF-06651600 or Placebo;   Drug: PF-06700841 or Placebo;   Drug: PF-06700841;   Drug: PF-06651600
  Sponsor:   Pfizer
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

  NCT03914625

  Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
  Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

  NCT03581292

  Conditions:   Anaplastic Astrocytoma;   Glioblastoma;   Malignant Glioma
  Interventions:   Radiation: Radiation Therapy;   Drug: Temozolomide;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
  Intervention:   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  NCT03213704

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
  Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gene Mutation;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652

  Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation
  Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03210714

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Langerhans Cell Histiocytosis;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

  NCT03057626

  Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
  Recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579

  Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
  Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.

  NCT04072835

  Condition:   Paroxysmal Supraventricular Tachycardia
  Intervention:   Drug: Etripamil NS
  Sponsors:   Milestone Pharmaceuticals Inc.;   IQVIA Biotech
  Recruiting
• A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

  NCT03953079

  Condition:   Neovascular Age-Related Macular Degeneration
  Interventions:   Drug: Drug: GB-102;   Drug: Aflibercept
  Sponsor:   Graybug Vision
  Recruiting
• Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

  NCT03918629

  Condition:   Clostridium Difficile Associated Disease
  Interventions:   Biological: Clostridium difficile;   Biological: Placebo
  Sponsor:   Pfizer
  Recruiting
• A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Patients Refractory to Conventional Therapy

  NCT03905512

  Condition:   Chronic Gout
  Interventions:   Drug: SEL-212;   Drug: SEL-037;   Drug: SEL-110;   Drug: KRYSTEXXA®
  Sponsor:   Selecta Biosciences, Inc.
  Recruiting
• Florida Pancreas Collaborative Next Generation Biobank

  NCT03851133

  Conditions:   Pancreatic Cancer;   Cancer Cachexia
  Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
  Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
  Recruiting
• Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

  NCT03833154

  Condition:   Carcinoma, Non-Small-Cell Lung
  Interventions:   Drug: Durvalumab;   Other: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation

  NCT03683030

  Condition:   Atrial Fibrillation
  Intervention:   Device: Radiofrequency Ablation
  Sponsor:   Biosense Webster, Inc.
  Recruiting
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.

  NCT03682705

  Condition:   Rheumatoid Arthritis (RA)
  Interventions:   Drug: Upadacitinib;   Drug: ABBV-105;   Drug: Upadacitinib placebo;   Drug: ABBV-105 placebo
  Sponsor:   AbbVie
  Recruiting
• A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  NCT03675308

  Condition:   Psoriatic Arthritis
  Interventions:   Biological: placebo for rizankizumab;   Biological: risankizumab
  Sponsor:   AbbVie
  Recruiting
• A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

  NCT03671148

  Condition:   Psoriatic Arthritis
  Interventions:   Biological: placebo for rizankizumab;   Biological: risankizumab
  Sponsor:   AbbVie
  Recruiting
• An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

  NCT03599622

  Conditions:   Granulomatous Colitis;   Crohn's Disease;   Crohn's Enteritis;   Granulomatous Enteritis
  Interventions:   Drug: BMS-986165;   Other: Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Mirikizumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Mirikizumab;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease

  NCT03395184

  Condition:   Crohn's Disease
  Interventions:   Drug: Placebo PF-06651600;   Drug: Placebo PF-06700841;   Drug: PF-06651600;   Drug: PF-06700841
  Sponsor:   Pfizer
  Recruiting
• Hemodynamic-GUIDEd Management of Heart Failure

  NCT03387813

  Conditions:   Heart Failure;   Heart Failure, Systolic;   Heart Failure, Diastolic;   Heart Failure NYHA Class II;   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV;   Heart Failure，Congestive;   Heart Failure With Reduced Ejection Fraction;   Heart Failure With Normal Ejection Fraction;   Heart Failure; With Decompensation
  Intervention:   Device: CardioMEMS™ HF System
  Sponsor:   Abbott Medical Devices
  Recruiting
• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

  NCT03350815

  Condition:   Ankylosing Spondylitis
  Interventions:   Drug: 150 mg open-label secukinumab;   Drug: 150 mg double-blinded secukinumab;   Drug: 300 mg double-blinded secukinumab
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

  NCT03345849

  Condition:   Crohn's Disease
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

  NCT03345836

  Condition:   Crohn's Disease
  Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
  Sponsor:   AbbVie
  Recruiting
• DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

  NCT03321513

  Condition:   Diabetic Macular Edema
  Interventions:   Drug: intravitreous aflibercept;   Drug: Bevacizumab + Deferred Aflibercept Group
  Sponsor:   Jaeb Center for Health Research
  Recruiting
• QP ExCELs: MultiPole Pacing (MPP) Sub-Study

  NCT03155724

  Condition:   Heart Failure
  Intervention:   Device: MultiPole Pacing
  Sponsor:   Biotronik, Inc.
  Recruiting
• Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

  NCT03108456

  Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
  Interventions:   Device: Orbital Atherectomy;   Device: Balloon
  Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
  Recruiting
• MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study

  NCT03072927

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: MILD
  Sponsor:   Vertos Medical, Inc.
  Recruiting
• ADAPT - A Patient Registry of the Real-world Use of Orenitram®

  NCT03045029

  Condition:   Pulmonary Arterial Hypertension
  Intervention:   Drug: Oral treprostinil
  Sponsor:   United Therapeutics
  Recruiting
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

  NCT02998528

  Condition:   Non Small Cell Lung Cancer
  Interventions:   Biological: Nivolumab;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ipilimumab
  Sponsors:   Bristol-Myers Squibb;   Ono Pharmaceutical Co. Ltd
  Recruiting
• Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief

  NCT02995733

  Condition:   Asthma
  Intervention:   Drug: PARTICS using QVAR
  Sponsors:   Brigham and Women's Hospital;   Patient-Centered Outcomes Research Institute;   American Academy of Family Physicians
  Recruiting
• Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)

  NCT02855164

  Condition:   Non-alcoholic Steatohepatitis (NASH)
  Interventions:   Drug: Tropifexor (LJN452);   Drug: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes

  NCT02785120

  Condition:   Ischemic Stroke
  Intervention:   Drug: TF0023
  Sponsor:   Techfields Inc
  Recruiting
• A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  NCT02782104

  Condition:   Depressive Disorder, Treatment-Resistant
  Intervention:   Drug: Esketamine Nasal Spray
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

  NCT02630316

  Conditions:   Pulmonary Hypertension;   Interstitial Lung Disease;   Combined Pulmonary Fibrosis and Emphysema
  Interventions:   Drug: Inhaled Treprostinil;   Drug: Placebo
  Sponsor:   United Therapeutics
  Recruiting
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

  NCT02565511

  Condition:   Alzheimer's Disease
  Interventions:   Biological: CAD106 Immunotherapy;   Other: Placebo to CAD106;   Drug: CNP520;   Other: Placebo to CNP520
  Sponsors:   Novartis Pharmaceuticals;   Banner Alzheimer's Institute;   National Institute on Aging (NIA);   Alzheimer's Association;   Amgen
  Recruiting
• Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

  NCT02290028

  Condition:   Heart Failure
  Intervention:   Device: Sentus QP left ventricular lead
  Sponsors:   Biotronik SE & Co. KG;   Biotronik, Inc.
  Recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250

  Conditions:   Advanced Malignant Solid Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis

  NCT01885078

  Condition:   Rheumatoid Arthritis
  Interventions:   Drug: Baricitinib;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

  NCT01872975

  Conditions:   Stage IB Breast Cancer;   Stage II Breast Cancer
  Interventions:   Radiation: regional nodal XRT;   Radiation: chestwall XRT;   Radiation: WBI
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
  Recruiting
• A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

  NCT03355209

  Condition:   Lennox Gastaut Syndrome
  Interventions:   Drug: ZX008 0.2 or 0.8 mg/kg/day;   Drug: Matching Placebo
  Sponsor:   Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
  Recruiting
• Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma

  NCT03126916

  Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma;   NMYC Gene Amplification;   Recurrent Neuroblastoma
  Interventions:   Biological: Aldesleukin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994

  Condition:   Leukemia
  Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Incyte Corporation;   Children's Oncology Group
  Recruiting
• Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

  NCT03653091

  Condition:   Type 2 Diabetes
  Interventions:   Device: Duodenal Mucosal Resurfacing (DMR);   Device: Duodenal Mucosal Resurfacing Sham (Sham)
  Sponsor:   Fractyl Laboratories, Inc.
  Recruiting
• A Phase I Study for Safety and Tolerability of AL002.

  NCT03635047

  Conditions:   Healthy;   Alzheimer Disease
  Interventions:   Biological: AL002;   Other: Saline Solution
  Sponsor:   Alector Inc.
  Recruiting
• Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia

  NCT03593213

  Condition:   Schizophrenia
  Interventions:   Drug: Cariprazine;   Drug: Placebo
  Sponsor:   Forest Laboratories
  Recruiting
• A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

  NCT03559192

  Condition:   Depressive Disorder, Major
  Interventions:   Drug: JNJ-67953964;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

  NCT03351244

  Condition:   Schizophrenia
  Interventions:   Drug: BI 409306;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• AMPLATZER PFO Occluder Post Approval Study

  NCT03309332

  Conditions:   Stroke;   Patent Foramen Ovale
  Intervention:   Device: AMPLATZER™ PFO Occluder
  Sponsor:   Abbott Medical Devices
  Recruiting
• Trial of Inhaled Molgramostim in CF Subjects With NTM Infection

  NCT03597347

  Conditions:   Mycobacterium Infections, Nontuberculous;   Cystic Fibrosis (CF)
  Interventions:   Drug: Molgramostim nebulizer solution;   Device: PARI eFlow nebulizer system
  Sponsor:   Savara Inc.
  Recruiting
• SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

  NCT03204318

  Condition:   Endometriosis Related Pain
  Interventions:   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix
  Sponsor:   Myovant Sciences GmbH
  Recruiting
• Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  NCT03150693

  Condition:   B Acute Lymphoblastic Leukemia
  Interventions:   Drug: Allopurinol;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Dexamethasone;   Drug: Pegylated L-Asparaginase;   Drug: Methotrexate;   Procedure: Bone Marrow Aspiration and Biopsy;   Drug: Cyclophosphamide;   Drug: Mercaptopurine;   Biological: Rituximab;   Drug: Doxorubicin;   Drug: Thioguanine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Short-term Clinical Deterioration After Acute Pulmonary Embolism

  NCT03915925

  Condition:   Pulmonary Embolism
  Intervention:  
  Sponsors:   Atrium Health;   Agency for Healthcare Research and Quality (AHRQ)
  Recruiting
• Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors

  NCT00785525

  Condition:   Healthy
  Intervention:   Drug: Filgrastim
  Sponsors:   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
  Recruiting
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

  NCT03398148

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: risankizumab IV;   Drug: placebo for risankizumab;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065

  NCT03398135

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: risankizumab;   Drug: placebo for risankizumab
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

  NCT03381196

  Condition:   Influenza A
  Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients

  NCT03181932

  Conditions:   MRSA;   Cystic Fibrosis
  Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
  Sponsor:   Savara Inc.
  Recruiting
• A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing

  NCT03495297

  Condition:   Ventricular Arrythmia
  Intervention:   Procedure: ommitence of defibrillation testing
  Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Boston Scientific Corporation
  Recruiting
• Validation of Software for Assessment of Atrial Fibrillation From Data Acquired by a Wearable Smartwatch

  NCT04176926

  Condition:   Atrial Fibrillation
  Intervention:   Diagnostic Test: Electrocardiogram
  Sponsor:   Fitbit Inc
  Recruiting
• Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

  NCT03927027

  Conditions:   Breast Cancer Stage I;   Breast Cancer Stage II;   Breast Cancer Stage III
  Interventions:   Drug: Isosulfan Blue;   Procedure: Axillary Lymph Node Dissection;   Procedure: Mapping;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Pan Tumor Nivolumab Rollover Study

  NCT03899155

  Condition:   Cancer
  Intervention:   Drug: Nivolumab
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Heart EXPAND Continued Access Protocol

  NCT03835754

  Condition:   Heart Transplant
  Intervention:   Device: OCS Heart System
  Sponsor:   TransMedics
  Recruiting
• A Proof of Concept Study of GSK3640254 in Human Immunodeficiency Virus-1 (HIV-1) Infected Treatment-naive Adults

  NCT03784079

  Condition:   HIV Infections
  Interventions:   Drug: GSK3640254;   Drug: Placebo matching GSK3640254 Mesylate salt
  Sponsor:   ViiV Healthcare
  Recruiting
• Prospective Evaluation of Open Irrigated Ablation Catheters With High Resolution Mapping to Treat Paroxysmal Atrial Fibrillation

  NCT03729830

  Condition:   Paroxysmal Atrial Fibrillation
  Intervention:   Device: Boston Scientific Open Irrigated Ablation Catheters
  Sponsor:   Boston Scientific Corporation
  Recruiting
• BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

  NCT03648541

  Condition:   Colitis, Ulcerative
  Interventions:   Drug: Spesolimab IV infusion;   Drug: Spesolimab SC solution for injection
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease

  NCT03533257

  Condition:   Alzheimer Disease
  Interventions:   Drug: AMX0035;   Drug: Placebo
  Sponsors:   Amylyx Pharmaceuticals Inc.;   Alzheimer’s Drug Discovery Foundation;   Alzheimer's Association
  Recruiting
• A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL

  NCT03467373

  Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
  Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Prospective, Multi-Center Evaluation of the ECHELON CIRCULAR Powered Stapler in Left-Sided Colorectal Anastomoses

  NCT03326895

  Condition:   Left-sided Colon Resection
  Intervention:   Device: Left-sided colon resection
  Sponsor:   Ethicon Endo-Surgery
  Recruiting
• INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

  NCT03037164

  Condition:   Anemia
  Interventions:   Device: INTERCEPT Blood System for Red Blood Cells;   Device: Conventional (Control)
  Sponsor:   Cerus Corporation
  Recruiting
• Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

  NCT03018288

  Condition:   Glioblastoma
  Interventions:   Drug: Pembrolizumab;   Biological: HSPPC-96;   Drug: Temozolomide;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Feasibility Study of the Intravascular Ventricular Assist System (iVAS)

  NCT02645539

  Conditions:   Heart Failure NYHA Class III;   Heart Failure NYHA Class IV
  Intervention:   Device: intravascular ventricular assist system (iVAS)
  Sponsor:   NuPulseCV
  Recruiting
• A Study of YH25448 in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT04075396

  Condition:   Carcinoma, Non-Small-Cell Lung
  Intervention:   Drug: YH25448
  Sponsors:   Janssen Research & Development, LLC;   Yuhan Corporation
  Recruiting
• S1803, Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

  NCT04071457

  Condition:   Multiple Myeloma
  Interventions:   Drug: Lenalidomide;   Drug: Daratumumab/rHuPH20
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Janssen, LP;   Adaptive
  Recruiting
• Molecular Transducers of Physical Activity Consortium

  NCT03960827

  Condition:   Physical Activity
  Interventions:   Other: Endurance Training;   Other: Restistance Training
  Sponsors:   University of Florida;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Stanford University;   Broad Institute;   Duke University;   Emory University;   Icahn School of Medicine at Mount Sinai;   Mayo Clinic;   Pacific Northwest National Laboratory;   University of Michigan;   Wake Forest University Health Sciences;   Wake Forest University;   University of Vermont;   National Institutes of Health (NIH)
  Recruiting
• An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

  NCT03873402

  Condition:   Renal Cell Carcinoma
  Interventions:   Biological: Nivolumab;   Biological: Ipilimumab;   Other: Ipilimumab placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

  NCT03786094

  Conditions:   Metastatic Breast Cancer;   Locally Recurrent Breast Cancer
  Interventions:   Drug: Eribulin;   Drug: Balixafortide
  Sponsor:   Polyphor Ltd.
  Recruiting
• The SNAP Trial: SPRINT® Peripheral Nerve Stimulation for the Treatment of Neuropathic Post-Amputation Pain

  NCT03783689

  Conditions:   Neuropathic Pain;   Amputation
  Intervention:   Device: SPRINT Peripheral Nerve Stimulation (PNS) System
  Sponsor:   SPR Therapeutics, Inc.
  Recruiting
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND - OUTREACH)

  NCT03744676

  Conditions:   Lymphoma, Non-Hodgkin;   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasms;   Neoplasms by Histologic Type;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Disorder
  Intervention:   Biological: lisocabtagene maraleucel
  Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation
  Recruiting
• Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

  NCT03234465

  Condition:   Oral Mucositis
  Interventions:   Biological: AG013;   Other: Placebo
  Sponsor:   Oragenics, Inc.
  Recruiting
• Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer

  NCT03088813

  Condition:   Small Cell Lung Cancer
  Interventions:   Drug: Irinotecan liposome injection;   Drug: Topotecan
  Sponsor:   Ipsen
  Recruiting
• A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

  NCT03032172

  Condition:   Spinal Muscular Atrophy
  Intervention:   Drug: Risdiplam
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency

  NCT04147936

  Condition:   Hepatic Insufficiency
  Interventions:   Dietary Supplement: AXA1665;   Dietary Supplement: Placebo
  Sponsor:   Axcella Health, Inc
  Recruiting
• A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

  NCT02570854

  Condition:   Anemia, Iron-Deficiency
  Interventions:   Biological: CSJ137;   Drug: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

  NCT04041284

  Conditions:   Migraine;   Major Depressive Disorder
  Interventions:   Drug: Fremanezumab;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

  NCT03992066

  Condition:   Anemia Associated With Chronic Kidney Disease
  Interventions:   Drug: Vadadustat;   Drug: Darbepoetin alfa;   Drug: Epoetin alfa
  Sponsor:   Akebia Therapeutics
  Recruiting
• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

  NCT03924856

  Condition:   Urinary Bladder Cancer, Muscle-invasive
  Interventions:   Drug: Pembrolizumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]);   Drug: Placebo
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

  NCT02361346

  Conditions:   Non-Hodgkin's B-cell Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell;   Small Lymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Blood Cancer;   Hematological Malignancy
  Interventions:   Drug: MT-3724 Phase 1;   Drug: MT-3724 Phase 2
  Sponsor:   Molecular Templates, Inc.
  Recruiting
• Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform

  NCT03697980

  Condition:   Chronic Heart Failure
  Intervention:   Device: HeartWare Ventricular Assist Device
  Sponsor:   Medtronic Cardiac Rhythm and Heart Failure
  Recruiting
• A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

  NCT03535740

  Condition:   ALK-positive Advanced NSCLC
  Intervention:   Drug: Brigatinib
  Sponsor:   Ariad Pharmaceuticals
  Recruiting
• Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment

  NCT03132675

  Condition:   Stage III/IV Melanoma
  Interventions:   Biological: tavokinogene telseplasmid;   Biological: Pembrolizumab;   Device: ImmunoPulse
  Sponsor:   OncoSec Medical Incorporated
  Recruiting
• A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

  NCT04060862

  Condition:   Breast Cancer
  Interventions:   Drug: Ipatasertib;   Drug: Placebo;   Drug: Palbociclib;   Drug: Fulvestrant
  Sponsor:   Hoffmann-La Roche
  Recruiting
• MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

  NCT03962543

  Conditions:   Plexiform Neurofibroma;   Neurofibromatosis Type 1 (NF1)
  Intervention:   Drug: PD-0325901 oral capsule
  Sponsor:   SpringWorks Therapeutics, Inc.
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer (NSCLC)(MK-7902-007/E7080-G000-314/LEAP-007)

  NCT03829332

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: Placebo for lenvatinib
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures

  NCT02688855

  Condition:   Bimalleolar Ankle Fractures
  Interventions:   Device: Active Combined Magnetic Field OL1000 Bone Growth Stimulator;   Device: Sham Combined Magnetic Field OL1000 Bone Growth Stimulator
  Sponsor:   Encore Medical, L.P.
  Recruiting
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

  NCT03822468

  Condition:   Breast Cancer
  Interventions:   Drug: Ribociclib;   Drug: Letrozole or Anastrozole;   Drug: Goserelin
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326

  Conditions:   Advanced Solid Tumors;   Triple Negative Breast Cancer;   Ovarian Cancer;   Gastric Cancer;   Colorectal Cancer;   Glioblastoma;   Biliary Tract Cancers
  Interventions:   Biological: Pembrolizumab;   Drug: Lenvatinib
  Sponsors:   Merck Sharp & Dohme Corp.;   Eisai Inc.
  Recruiting
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease

  NCT03782376

  Condition:   Crohn Disease
  Interventions:   Drug: Ustekinumab approximately 6 mg/kg (IV);   Drug: Placebo (SC);   Drug: Placebo (IV);   Drug: Ustekinumab 90 mg (SC) Group 1;   Drug: Ustekinumab 90 mg (SC) Group 2
  Sponsor:   Janssen-Cilag Ltd.
  Recruiting
• A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03653026

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
  Sponsor:   AbbVie
  Recruiting
• A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

  NCT03695380

  Condition:   OVARIAN CANCER
  Interventions:   Drug: Cobimetinib;   Drug: Niraparib;   Drug: Atezolizumab
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

  NCT03517722

  Condition:   Lupus Erythematosus, Systemic
  Interventions:   Drug: Placebo;   Drug: Ustekinumab (approximately 6 mg/kg);   Drug: Ustekinumab 90 mg
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer

  NCT03561220

  Condition:   Prostate Cancer
  Interventions:   Radiation: Standard of Care IMRT (Photon);   Radiation: Standard of Care Proton Therapy;   Radiation: Proton Arm 1: Standard Proton Therapy;   Radiation: Proton Arm 2: Hypofractionated Proton Therapy
  Sponsors:   University of Florida;   Patient-Centered Outcomes Research Institute
  Recruiting
• An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

  NCT03467958

  Condition:   Crohn Disease
  Intervention:   Drug: Ozanimod
  Sponsor:   Celgene
  Recruiting
• A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression

  NCT03543410

  Conditions:   Depressive Episode;   Bipolar 1 Depression
  Interventions:   Drug: SEP-4199 200 mg;   Drug: SEP-4199 400 mg;   Drug: Placebo
  Sponsor:   Sunovion
  Recruiting
• A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

  NCT03464097

  Condition:   Crohn Disease
  Interventions:   Drug: Ozanimod;   Other: Placebo
  Sponsor:   Celgene
  Recruiting
• JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

  NCT03538301

  Condition:   Idiopathic Pulmonary Fibrosis
  Interventions:   Drug: ND-L02-s0201;   Other: Other: Placebo
  Sponsor:   Nitto Denko Corporation
  Recruiting
• BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis

  NCT03482635

  Condition:   Colitis, Ulcerative
  Interventions:   Drug: Spesolimab;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

  NCT03412565

  Condition:   Multiple Myeloma
  Interventions:   Drug: Daratumumab;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Carfilzomib
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

  NCT03393013

  Conditions:   Systemic Lupus Erythematosus;   Lupus Nephritis
  Interventions:   Drug: KZR-616;   Drug: Placebo
  Sponsor:   Kezar Life Sciences, Inc.
  Recruiting
• A Safety Extension Study of SHP647 in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085

  Conditions:   Crohn's Disease;   Ulcerative Colitis
  Interventions:   Drug: 25 mg SHP647;   Drug: 75 mg SHP647
  Sponsor:   Shire
  Recruiting
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

  NCT04029688

  Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Neuroblastoma;   Solid Tumors
  Interventions:   Drug: Idasanutlin;   Drug: Venetoclax;   Drug: Cyclophosphamide;   Drug: Topotecan;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Intrathecal Chemotherapy
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

  NCT04046939

  Conditions:   Eosinophilic Asthma;   Asthma
  Interventions:   Drug: low-dose dexpramipexole;   Drug: mid-dose dexpramipexole;   Drug: high-dose dexpramipexole;   Drug: placebo oral tablet
  Sponsor:   Knopp Biosciences
  Recruiting
• A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

  NCT03105128

  Condition:   Crohn's Disease
  Interventions:   Drug: placebo for risankizumab;   Drug: risankizumab IV;   Drug: risankizumab SC
  Sponsor:   AbbVie
  Recruiting
• Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

  NCT03108495

  Condition:   Cervical Carcinoma
  Interventions:   Biological: LN-145;   Biological: LN-145 + pembrolizumab
  Sponsor:   Iovance Biotherapeutics, Inc.
  Recruiting
• Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

  NCT03901339

  Condition:   Metastatic Breast Cancer
  Interventions:   Drug: Sacituzumab Govitecan;   Drug: Eribulin;   Drug: Capecitabine;   Drug: Gemcitabine;   Drug: Vinorelbine
  Sponsor:   Immunomedics, Inc.
  Recruiting
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

  NCT03881059

  Condition:   Active Psoriatic Arthritis
  Interventions:   Other: BMS-986165 Placebo;   Drug: BMS-986165 Dose A;   Drug: BMS-986165 Dose B;   Drug: Ustekinumab;   Other: Ustekinumab Placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

  NCT03077412

  Condition:   Fistulizing Crohn's Disease
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
  Sponsors:   Gilead Sciences;   Galapagos NV
  Recruiting
• Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

  NCT03046056

  Condition:   Small Bowel Crohn's Disease
  Interventions:   Drug: Filgotinib;   Drug: Placebo to match filgotinib
  Sponsors:   Gilead Sciences;   Galapagos NV
  Recruiting
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

  NCT04186871

  Conditions:   Autoimmune Disorder;   Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Primary Sjögren's Syndrome
  Interventions:   Drug: branebrutinib;   Drug: abatacept;   Drug: branebrutinib placebo
  Sponsor:   Bristol-Myers Squibb
  Recruiting
• A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

  NCT04172831

  Condition:   Fibromyalgia
  Interventions:   Drug: TNX-102 SL;   Drug: Placebo SL Tablet
  Sponsor:   Tonix Pharmaceuticals, Inc.
  Recruiting
• A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

  NCT04166773

  Condition:   Nonalcoholic Steatohepatitis
  Interventions:   Drug: Tirzepatide;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

  NCT03706833

  Conditions:   Degenerative Mitral Valve Disease;   Mitral Regurgitation;   Mitral Insufficiency;   Functional Mitral Regurgitation
  Interventions:   Device: Edwards PASCAL System;   Device: Abbott Mitraclip System
  Sponsor:   Edwards Lifesciences
  Recruiting
• Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753

  Condition:   Primary Generalized Epilepsy
  Interventions:   Drug: Cenobamate;   Drug: Placebo
  Sponsor:   SK Life Science, Inc.
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT02819635

  Condition:   Ulcerative Colitis (UC)
  Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
  Sponsor:   AbbVie
  Recruiting
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634

  Condition:   Chronic Obstructive Pulmonary Disease
  Interventions:   Biological: Benralizumab;   Biological: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

  NCT03631199

  Condition:   Non-small Cell Lung Cancer
  Interventions:   Drug: canakinumab;   Drug: canakinumab matching placebo;   Drug: pembrolizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: nab-paclitaxel;   Drug: pemetrexed
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

  NCT04044664

  Condition:   Post-Traumatic Stress Disorder
  Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
  Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
  Recruiting
• Tezepelumab COPD Exacerbation Study

  NCT04039113

  Condition:   Chronic Obstructive Pulmonary Disease (COPD)
  Interventions:   Biological: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005

  Condition:   Multiple Sclerosis, Primary Progressive
  Interventions:   Drug: Ocrelizumab;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Recruiting
• A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

  NCT04019561

  Conditions:   Non-alcoholic Fatty Liver Disease (NAFLD);   Non-alcoholic Steatohepatitis (NASH)
  Interventions:   Drug: MEDI0382 high dose;   Drug: Placebo for MEDI0382 high dose;   Drug: MEDI0382 low dose;   Drug: Placebo for MEDI0382 low dose
  Sponsor:   MedImmune LLC
  Recruiting
• A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia

  NCT04009577

  Condition:   Insomnia
  Interventions:   Drug: LEM 5 mg;   Drug: LEM 10 mg
  Sponsor:   Eisai Inc.
  Recruiting
• A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Subjects With Major Depressive Disorder

  NCT04007367

  Condition:   Major Depressive Disorder
  Interventions:   Drug: SAGE-217;   Drug: Placebo
  Sponsor:   Sage Therapeutics
  Recruiting
• A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2

  NCT04003142

  Condition:   Hot Flashes
  Interventions:   Drug: fezolinetant;   Drug: placebo
  Sponsor:   Astellas Pharma Global Development, Inc.
  Recruiting
• Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

  NCT04000009

  Condition:   Adjunctive Treatment of Major Depressive Disorder
  Intervention:   Drug: Pimavanserin
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair

  NCT02803957

  Condition:   Mitral Valve Insufficiency
  Interventions:   Device: NeoChord DS1000;   Device: Surgical Mitral Valve Repair
  Sponsor:   NeoChord
  Recruiting
• Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

  NCT02717507

  Condition:   Cancer Survivor
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (CLARITY-2)

  NCT03968159

  Condition:   Adjunctive Treatment of Major Depressive Disorder
  Interventions:   Drug: Pimavanserin;   Drug: Placebo
  Sponsor:   ACADIA Pharmaceuticals Inc.
  Recruiting
• A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia

  NCT03965091

  Condition:   Fibromyalgia
  Interventions:   Drug: Fremanezumab - Dose A;   Drug: Fremanezumab - Dose B;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Recruiting
• De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

  NCT03952585

  Conditions:   Basaloid Squamous Cell Carcinoma;   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Oropharyngeal Squamous Cell Carcinoma;   Papillary Squamous Cell Carcinoma;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  Interventions:   Drug: Cisplatin;   Radiation: Image Guided Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449

  Condition:   Endometrial Neoplasms
  Interventions:   Drug: Pembrolizumab;   Drug: Lenvatinib;   Drug: Paclitaxel;   Drug: Doxorubicin
  Sponsors:   Eisai Inc.;   Merck Sharp & Dohme Corp.
  Recruiting